Entasis Therapeutics Holdings Inc (ETTX) Stock Price, Quote, News and Overview
NASDAQ:ETTX - Nasdaq - US2936141033 - Common Stock
ETTX Quote, Performance and Key Statistics
Entasis Therapeutics Holdings Inc
NASDAQ:ETTX (7/8/2022, 8:00:02 PM)
2.19
-0.01 (-0.45%)
The current stock price of ETTX is 2.19 null. In the past year, price decreased by -12.05%.
ETTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ETTX
Company Profile
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-09-26. The firm is focused on the discovery, development, and commercialization of targeted antibacterial products that address unmet medical needs to treat infections caused by multidrug-resistant pathogens. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), which is an intravenous, combination of sulbactam, an IV b-lactam antibiotic, and durlobactam, a novel broad-spectrum IV b -lactamase inhibitor (BLI) for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Its second late-stage product candidate is zoliflodacin, which is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. Its third product candidate is ETX0282CPDP for the oral treatment of urinary tract infections. ETX0282CPDP is a combination of ETX0282, a novel oral BLI, with cefpodoxime proxetil (cefpodoxime), an oral b-lactam antibiotic.
Company Info
Entasis Therapeutics Holdings Inc
35 Gatehouse Drive
Waltham MASSACHUSETTS 02451 US
CEO: Manoussos Perros
Employees: 51
Company Website: https://www.entasistx.com/
Phone: 17818100120.0
Entasis Therapeutics Holdings Inc / ETTX FAQ
What is the stock price of Entasis Therapeutics Holdings Inc today?
The current stock price of ETTX is 2.19 null. The price decreased by -0.45% in the last trading session.
What is the ticker symbol for Entasis Therapeutics Holdings Inc stock?
The exchange symbol of Entasis Therapeutics Holdings Inc is ETTX and it is listed on the Nasdaq exchange.
On which exchange is ETTX stock listed?
ETTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Entasis Therapeutics Holdings Inc stock?
8 analysts have analysed ETTX and the average price target is 2.04 null. This implies a price decrease of -6.85% is expected in the next year compared to the current price of 2.19. Check the Entasis Therapeutics Holdings Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Entasis Therapeutics Holdings Inc worth?
Entasis Therapeutics Holdings Inc (ETTX) has a market capitalization of 104.80M null. This makes ETTX a Micro Cap stock.
How many employees does Entasis Therapeutics Holdings Inc have?
Entasis Therapeutics Holdings Inc (ETTX) currently has 51 employees.
What are the support and resistance levels for Entasis Therapeutics Holdings Inc (ETTX) stock?
Entasis Therapeutics Holdings Inc (ETTX) has a support level at 2.19 and a resistance level at 2.19. Check the full technical report for a detailed analysis of ETTX support and resistance levels.
Should I buy Entasis Therapeutics Holdings Inc (ETTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ETTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ETTX, evaluating the profitability, health, valuation and growth aspects
- Entasis Therapeutics Holdings Inc (ETTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Entasis Therapeutics Holdings Inc (ETTX) Sales and EPS estimates to see what analysts future expectations are.
- Entasis Therapeutics Holdings Inc (ETTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Entasis Therapeutics Holdings Inc (ETTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- Entasis Therapeutics Holdings Inc (ETTX) Stock Chart to make your own analysis
- Entasis Therapeutics Holdings Inc (ETTX) Latest news and press-releases to stay up to date.
Does Entasis Therapeutics Holdings Inc (ETTX) stock pay dividends?
ETTX does not pay a dividend.
When does Entasis Therapeutics Holdings Inc (ETTX) report earnings?
Entasis Therapeutics Holdings Inc (ETTX) will report earnings on 2022-08-09.
What is the Price/Earnings (PE) ratio of Entasis Therapeutics Holdings Inc (ETTX)?
Entasis Therapeutics Holdings Inc (ETTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.12).
ETTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ETTX. When comparing the yearly performance of all stocks, ETTX is one of the better performing stocks in the market, outperforming 90.67% of all stocks.
ETTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ETTX. ETTX may be in some trouble as it scores bad on both profitability and health.
ETTX Financial Highlights
Over the last trailing twelve months ETTX reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS increased by 28.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -117.26% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ETTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 48% to ETTX. The Buy consensus is the average rating of analysts ratings from 8 analysts.